This post was originally published on this site Following promising early efficacy results for a cirmtuzumab–Imbruvica treatment combo, a Phase 2 clinical trial has now been opened to people with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The opening of this randomized trial was based on the promising results seen in the prior Phase 1 stage, in…
Conditions
Conditions
Understanding Protein Aggregation May Aid Quest for Better Alzheimer’s Treatments
This post was originally published on this site Better understanding the mathematics behind how protein clumps form — and how therapies interfere with this process — may improve treatment strategies for Alzheimer’s, and other diseases, new research suggests. The study, “Optimal control strategies for inhibition of protein aggregation,” was published in PNAS. Protein aggregation is the term…
USPSTF Updates Recommendations on Testing for BRCA-related Cancers in Women
This post was originally published on this site The United States Preventive Services Task Force (USPSTF) has revised their recommendations on testing for cancer-associated BRCA1/2 mutations in women, suggesting risk assessment only in those with a personal or family history of cancers associated with these mutations. These guidelines were published in the journal JAMA in a…
$102.2M Pelotonia Gift to Help Establish Immuno-Oncology Institute at OSU
This post was originally published on this site A $102.2 million Pelotonia donation will help establish an institute at Ohio State University (OSU) that will focus exclusively on groundbreaking immuno-oncology therapies and cures for cancer. Disbursed over five years, the funds will support research to be conducted by the Pelotonia Institute for Immuno-Oncology (PIIO) at the…
GSK’s Belantamab Mafodotin Shows Promise for Relapsed or Refractory Multiple Myeloma
This post was originally published on this site GlaxoSmithKline’s investigational antibody-drug conjugate, belantamab mafodotin (GSK2857916), demonstrated a clinically meaningful overall response rate in hard-to-treat multiple myeloma patients in a Phase 2 trial, with the trial meeting its primary goal. Findings from the open-label DREAMM-2 study (NCT03525678) — which is assessing the treatment as a fourth-line…
Expert Discusses Celsion’s Ovarian Cancer Immunotherapy GEN-1; Phase 1/2 Trial Still Enrolling
This post was originally published on this site The ovarian cancer immunotherapy candidate GEN-1, which is being tested in a Phase 1/2 clinical trial in newly diagnosed patients with advanced disease, was the focus of a recent call with a gynecologic oncology expert. The OVATION 2 trial (NCT03393884) is enrolling at 34 sites across the U.S. It…
Telix Enters Collaboration with DKFZ Researchers to Develop Image-Guided Surgery
This post was originally published on this site Telix Pharmaceuticals has established a collaboration agreement with a team of researchers from the German Cancer Research Center (Deutsches Krebsforschungszentrum, or DKFZ) to develop an innovative image-guided surgery for men with prostate cancer. Investigators from the DKFZ and Heidelberg University Clinic have been working on the development…
At NY Genome Center, Legal Expert Presents Ethical Dilemmas in Gene Editing
This post was originally published on this site Developing gene therapies for rare diseases is one thing. Creating gene-edited “designer babies” is quite another. German legal expert Timo Minssen outlined the potentially explosive ethical landmines surrounding such issues during a recent talk at the New York Genome Center. Minssen directs the Center for Advanced Studies…
FDA Clears Way for Trial of Immunotherapy in Advanced Prostate Cancer, Scripps Research Says
This post was originally published on this site The U.S. Food and Drug Administration (FDA) has signed off on a clinical trial that will test CCW702, an immunotherapy developed by Calibr at Scripps Research, as a possible treatment of metastatic castration-resistant prostate cancer (mCRPC). CCW702 is a bispecific antibody, acting as a bridge between cancer and…
3D Model Unravels How Beta-amyloid Weakens Brain-Blood Barrier, May Aid in Treatment Discovery
This post was originally published on this site A new 3D model using human cells grown on a chip can mimic what happens in the brain during Alzheimer’s and allow for the screening of possible therapies in a disease where so many fail, including medicines already approved for other conditions. This tissue model also helps…
Our Family’s Golden Retriever Is More Than Man’s Best Friend
This post was originally published on this site This week, pet lovers across the United States celebrated National Dog Day to bring awareness to the thousands of dogs that need rescuing. My golden retriever is celebrated every day. A last act of love Jack isn’t an official service dog, but he is a helper to…
Tecentriq-Abraxane Combo OK’d in EU to Treat Certain Advanced Triple-negative Breast Cancers
This post was originally published on this site The European Commission has approved the use of Roche‘s Tecentriq (atezolizumab) in combination with Abraxane (nab-paclitaxel) chemotherapy to treat certain adults with advanced triple-negative breast cancer (TNBC), an aggressive and difficult-to-treat malignancy. The combo is intended for people whose tumors cannot be removed by surgery (unresectable), are locally advanced or…